ADH-503

SKU: orb1299517

Description

ADH-503 (GB1275) is an orally active, allosteric agonist of CD11b. It reprograms tumor-associated macrophages, reduces immunosuppressive myeloid cell infiltration, and enhances dendritic cell activity. This small molecule is utilized in immuno-oncology research to study macrophage polarization and antitumor immune responses in both cellular and animal models.

Research Area

Immunology & Inflammation

Key Properties

• CAS Number: 2055362-74-6
• MW: 524.7
• Purity: >99.99% (May vary between batches)
• Formula: C₂₇H₂₈N₂O₅S₂
• SMILES: C[N+](C)(C)CCO.[O-]C(=O)c1ccc(cc1)-c1ccc(\C=C2/SC(=S)N(Cc3ccccc3)C2=O)o1
• Target: Complement System
• Solubility: DMSO:5.25 mg/mL (10.01 mM)

Bioactivity

• In Vivo:
  METHODS: ADH-503 (GB1275) (30, 100 mg/kg, oral) was administered to rats and C57/B6 mice to test the pharmacokinetics (PK) and safety. RESULTS The mean half-life of ADH-503 (GB1275) in rats and mice after administration was 4.68 and 3.95 hours, and the Cmax and AUC0-t in plasma were 1716 and 2594 ng/mL and 6950 and 13962 ng.h/mL, respectively.
• In Vitro:
  METHODS: ADH-503 (GB1275) (4 μM, 10 days) was used to investigate the expression of macrophage markers in two syngeneic orthotopic models. RESULTS After treatment with ADH-503 (GB1275), macrophages expressed higher levels of MHCI, MHCII, CD80, and CD86, indicating improved antigen presentation properties of the remaining macrophages.
• Animal Research:
  Animal Model:Male rats.Dosage:30,100 mg/kg (Pharmacokinetic Analysis). Administration:Oral gavage twice a day; on days 1 and 5

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Complement System, ComplementSystem, CD11b, dendritic, ADH503, ADH-503, ADH 503, allosteric, Inhibitor, GB1275, GB-1275, GB 1275, macrophages, orally, inhibit, immunosuppressive, repolarization, tumorassociated, tumor-infiltrating

Compound Identifiers

PubChem CID

145711124